Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

5 Oct 2009 07:00

RNS Number : 1958A
Immunodiagnostic Systems Hldgs PLC
05 October 2009
 



 

Immunodiagnostic Systems Holdings plc

Trading update

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of diagnostic testing kits for the clinical and research markets, announces a trading update for the six month period to 30 September 2009, prior to the release of its half-yearly report on Monday, 30 November 2009.

Turnover from continuing operations for the period is 56% ahead of the comparative period for last year at £16.9 million (2008: £10.8 million) and 20% ahead of 2008 H2 on a like for like basis. Revenues have increased in all direct sales territories with substantial growth in the USAFrance and Germany. Sales of our Vitamin D products continue to grow at an impressive rate, having doubled compared to same period last year.

The company has made progress in both sales and placements of our automated instrument the IDS-iSYS following its launch at the end of February this yearWe have also launched three automated products; 25 Hydroxy vitamin D at the end of February, P1NP in July and HGH in September. We have direct reagent rental accounts in the UK, FranceGermanyAustria 

and Switzerland and have made instrument sales in AustraliaCanadaFinlandItalySpainFrance and Switzerland.

The roll out of the IDS-iSYS is in its formative stages, and although initial machine sales are a little lower than anticipated, it is pleasing to report that revenue per machine is ahead of expectations. We expect the rate of sales and placements to increase in H2 following the increase in the number of iSYS evaluation sites towards the end of H1, the new agreement with Technogenetics (announced today on RNS Reach) under which we will supply OEM instruments and reagents to them, and, subject to the timing of FDA approval later this year, the planned US launch of the iSYS system.

Overall trading remains in line with management expectations and the Board remains confident going forward that it can continue to execute its plans for the current year.

Enquiries:

Immunodiagnostic Systems Holdings Plc

Tel: 0191 519 0660

Roger Duggan, CEO

Paul Hailes, Finance Director

Brewin Dolphin Investment Banking

Tel: 0845 213 4730

Andrew Emmott

Sean Wyndham-Quin

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTILFLTIRLSIIA
Date   Source Headline
28th Jun 201612:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20161:42 pmRNSDirector/PDMR Shareholding
22nd Jun 20167:45 amRNSAnnual Report and Accounts
22nd Jun 20167:00 amRNSPreliminary Results
9th Jun 20167:00 amRNSUpdate re Royalty Revenues
20th May 20169:20 amRNSHolding(s) in Company
6th May 201610:30 amRNSLaunch of IDS-iSYS 17-OH Progesterone assay
25th Apr 20167:00 amRNSFull Year Trading Update
8th Jan 20167:00 amRNSRelocation of Automated related Assay Activity
4th Jan 20167:30 amRNSPaul Martin joins as Group Finance Director
18th Dec 20159:43 amRNSLaunch of Salivary Cortisol Hypertension Assay
30th Nov 201510:41 amRNSHolding(s) in Company
24th Nov 20157:00 amRNSHalf Yearly Report
22nd Oct 20152:22 pmRNSDirectorate Change
21st Oct 20155:00 pmRNSHolding(s) in Company - Replacement
20th Oct 20152:23 pmRNSDirectorate Change
13th Oct 20157:00 amRNSTrading Statement
8th Oct 20154:40 pmRNSHolding(s) in Company
1st Oct 201512:05 pmRNSTotal Voting Rights
30th Sep 20152:05 pmRNSHolding(s) in Company
15th Sep 20154:32 pmRNSAdditional Listing
4th Aug 20152:43 pmRNSResult of AGM
4th Aug 20157:00 amRNSAGM Statement
29th Jun 20153:18 pmRNSRe Report and Accounts and AGM - Replacement
29th Jun 201511:59 amRNSRe Report and Accounts and AGM
29th Jun 20157:15 amRNSDirectorate Change
23rd Jun 20157:00 amRNSFinal Results
12th Jun 20154:00 pmRNSBoard Appointment
10th Jun 20157:00 amRNSDirectorate Change
29th May 20157:00 amRNSTrading Statement
21st Apr 20157:00 amRNSTrading Statement
2nd Apr 20157:43 amRNSPatricio Lacalle Joins as Chief Executive Officer
9th Feb 201510:30 amRNSHolding(s) in Company
3rd Feb 20157:00 amRNSDirectorate Change
6th Jan 20155:04 pmRNSAdditional Listing
5th Jan 20155:10 pmRNSAdditional Listing
24th Dec 20141:30 pmRNSDirectorate Change
19th Dec 201410:47 amRNSHolding(s) in Company
19th Dec 20148:40 amRNSHolding(s) in Company
18th Dec 20149:30 amRNSDirector/PDMR Shareholding
15th Dec 20145:13 pmRNSHolding(s) in Company
12th Dec 20147:00 amRNSLaunch of 1,25-Dihydroxy Vitamin D Assay
8th Dec 20143:38 pmRNSHolding(s) in Company
4th Dec 20145:36 pmRNSDirectorate Change
4th Dec 20144:27 pmRNSDirector/PDMR Shareholding
25th Nov 20147:00 amRNSDirectorate Change
25th Nov 20147:00 amRNSHalf Yearly Report
24th Nov 20145:20 pmRNSPatrik Dahlen Resigns as CEO
14th Oct 20147:00 amRNSTrading Update
15th Sep 20147:00 amRNSUpdate on current trading

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.